

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1.-5. (canceled).

6. (currently amended): The method according to claim 522 wherein the plasma protein is derived from human or animals.

7. (currently amended): The method according to claim 522 wherein the first drug is labeled with a radioactive nuclide, a fluorescent substance or a dye.

8. (currently amended): The method according to claim 522, wherein the plasma protein is serum albumin or acid glycoprotein, and the ~~two or more~~-second or more drugs bind to different binding sites of the plasma protein.

9. (currently amended): The method according to claim 7 wherein the ~~two or more~~-second or more drugs are labeled with the same or different substances respectively.

10. (currently amended): The method according to claim 9, wherein the ~~two or more~~-second or more drugs are labeled with different radioactive nuclides respectively, and these different radioactive nuclides can be separately measured simultaneously.

11. - 21. (canceled).

22. **(new):** A method for determining whether a first drug binds to a plasma protein at the same site as any of a second or more drugs for which the binding site is known, said method comprising:

mixing the first drug with the plasma protein and determining the ratio of free first drug to total first drug to give a first free first drug ratio;

mixing the second or more drugs with the first drug and the plasma protein and determining the ratio of free first drug to total first drug to give a second free first drug ratio; and

determining the ratio of the first free first drug ratio to the second free first drug ratio to give a change ratio, thereby determining whether the first drug binds to the plasma protein at the same site as any of the second or more drugs for which the binding site is known.